<DOC>
	<DOCNO>NCT02076516</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness CORACTO® ( Rapamycin®-Eluting coronary stent delivery system ) treatment two de novo lesion restenotic post-PTCA ( non-stented ) lesion locate two epicardial native coronary artery ( maximum one lesion per vessel ) suitable treatment stent 2.5 4.0 mm diameter &lt; 15 mm suitable treatment single CORACTO® stent population 100 patient .</brief_summary>
	<brief_title>Pilot Evaluation Of CORACTO® ( THE PILOT-SECRET TRIAL )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patient ≥ 18 year old . Patient eligible percutaneous coronary intervention ( PCI ) acceptable candidate coronary artery bypass grafting ( CABG ) . Clinical evidence ischemic heart disease and/or positive functional study , stable angina pectoris ( Canadian Cardiovascular Society Classification ( CCS ) 1 , 2 , 3 4 ) unstable angina pectoris ( Braunwald Class IBC , IIBC , IIIBC ) , silent ischemia . The target lesion ( ) target vessel ( ) meet ( ) follow criterion : 1 . The target lesion single de novo lesion native coronary artery . 2 . The stenosis target lesion ( ) ≥ 50 % &lt; 100 % ( visual estimation ) . 3 . The target lesion length must ≤ 15 mm . In case second stent require successful treatment , CORACTO® stent . 4 . The target reference vessel diameter must ( visual estimation ) suitable treatment stent 2.5 4.0 mm . Patient inform nature study , understand study requirement , agree provision provide write informed consent approve Institutional Review Board/Ethics Committee respective clinical site . The patient willing able comply specify followup evaluation . Most recent leave ventricular ejection fraction ( LVEF ) patient &lt; 25 % . Known allergy follow : aspirin , Clopidogrel bisulfate ( Plavix® ) , Prasugrel ( Effient® ) Ticlopidine ( Ticlid® ) , heparin , Rapamycin , stainless steel , Poly Lactic co glycolic acid contrast agent ( adequately premedicated ) . Platelet count le 100,000 cells/mm3 700,000 cells/mm3 . White Blood Cell count le 3,500 cells/mm3 . Evidence STsegment elevation acute myocardial infarction ( MI ) nonST segment elevation MI positive Troponin within 72 hour intend treatment . ANY previous PCI Planned stag procedure ( patient 2vessel disease treated procedure ) . Presence significant lesion &gt; 50 % stenosis ( visual estimation ) anywhere within target vessel Significant lesion nontarget vessel require interventional treatment within 30 day postprocedure Planned future interventional procedure target vessel . The target lesion ( ) require ( ) treatment device PTCA balloon prior stent placement . ( e.g . limited directional coronary atherectomy , excimer laser , rotational atherectomy , thrombus aspiration etc. ) . Previous stenting anywhere within target vessel ( ) Target vessel evidence thrombus Excessive tortuosity ( &gt; 60° ) target vessel proximal target lesion ( visual estimation ) . The target lesion ( ) follow characteristic ( visual estimation ) : 1 . Ostial bifurcation lesion ( within 3mm region origin target vessel , visual estimation ) . 2 . Target lesion involves side branch &gt; 2mm diameter . 3 . Moderate severely calcify lesion successfully predilated . 4 . Target lesion locate supply arterial venous bypass graft . 5 . A complete occlusion ( TIMI flow 0 1 ) . Target lesion locate leave main trunk . Stroke transient ischemic attack within 180 day prior baseline procedure . Active peptic ulcer upper GI bleeding within 180 day prior baseline procedure . The patient bleed haemorrhagic diathesis coagulopathy . The patient refuse blood transfusion . The patient widespread peripheral vascular disease . Acute chronic renal dysfunction ( creatinine clearance 40ml/m2 ) . The patient require multiple stent implantation tandem lesion . Life expectancy less 1 year . Patient currently participate investigational drug device study complete primary endpoint clinically interfere current study endpoint . In Investigator 's opinion patient ( ) comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study . Female childbearing potential , pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Drug-eluting Stent , Coronary Artery Disease</keyword>
</DOC>